Cisplatin in cancer therapy: Molecular mechanisms of action

European Journal of Pharmacology

Volumn 740, Issue , 2014, Pages 364-378

  Dasari, Shaloam ^a   Bernard Tchounwou, Paul ^a  

^a Cellomics and Toxicogenomics Research Laboratory College of Science Engineering and Technology Jackson State University ^*  (United States)

Author keywords

Cancer treatment; Cisplatin; Mechanisms of action; Platinum based drugs

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ANIMAL; COMBINATION DRUG THERAPY; HUMAN; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS;

EID: 84906544769     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.07.025     Document Type: Review

References (188)

1. T.J. Abrams, L.B. Lee, L.J. Murray, N.K. Pryer, and J.M. Cherrington SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol. Cancer Ther. 2 2003 471 478
2. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat. Rev. Cancer 3 2003 502 516
3. S.K. Aggarwal A histochemical approach to the mechanism of action of cisplatin and its analogues J. Histochem. Cytochem. 41 1993 1053 1073
4. S.K. Aggarwal Calcium modulation of toxicities due to cisplatin Met. Based Drugs 5 1998 77 81
5. S.K. Aggarwal, J.A. Broomhead, D.P. Fairlie, and M.W. Whitehouse Platinum drugs: combined anti-lymphoproliferative and nephrotoxicity assay in rats Cancer Chemother. Pharmacol. 4 1980 249 258
6. J.A. Ajani, K.A. Winter, L.L. Gunderson, J. Pedersen, A.B. Benson III, C.R. Thomas Jr., R.J. Mayer, M.G. Haddock, T.A. Rich, and C. Willett Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial JAMA 299 2008 1914 1921
7. Akron. 2009. The Chemical Database. The Department of Chemistry at the University of Akron. http://ull.chemistry.uakron.edu/erd and search on CAS number. (accessed 25.03.14.).
8. D.S. Alberts, M.R. Manning, S.W. Coulthard, C.F. Koopmann Jr., and T.S. Herman Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland Cancer 47 1981 645 648
9. A.A. Al-Majed Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats Basic Clin. Pharmacol. Toxicol. 100 2007 145 150
10. A.A. Al-Majed, M.M. Sayed-Ahmed, A.A. Al-Yahya, A.M. Aleisa, S.S. Al-Rejaie, and O.A. Al-Shabanah Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model Pharmacol. Res. 53 2006 278 286
11. M. Alizadehnohi, M. Nabiuni, Z. Nazari, Z. Safaeinejad, and S. Irian The synergistic cytotoxic effect of cisplatin and honey bee venom on human ovarian cancer cell line A2780cp J. Venom. Res. 3 2012 22 27
12. P. Apostolou, M. Toloudi, M. Chatziioannou, E. Ioannou, D.R. Knocke, J. Nester, D. Komiotis, and I. Papasotiriou AnvirzelTM in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines BMC Pharmacol. Toxicol. 14 2013 18
13. I. Arany, and R.L. Safirstein Cisplatin nephrotoxicity Semin. Nephrol. 23 2003 460 464
14. A. Ardizzoni, R. Rosso, F. Salvati, V. Fusco, A. Cinquegrana, P.M. De, J. Serrano, M.C. Pennucci, E. Soresi, and M. Crippa Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian lung cancer task force (FONICAP) phase II study Cancer 67 1991 2984 2987
15. H.J. Arts, H. Hollema, W. Lemstra, P.H. Willemse, E.G. De Vries, H.H. Kampinga, and A.G. Van der Zee Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis Int. J. Cancer 84 1999 234 238
16. A. Baniahmad, and M.J. Tsai Mechanisms of transcriptional activation by steroid hormone receptors J. Cell. Biochem. 51 1993 151 156
17. 2+to nucleic acid bases Inorg. Chem. 25 1986 684 688
18. A. Basu The potential of protein kinase C as a target for anticancer treatment Pharmacol. Ther. 59 1993 257 280
19. A. Basu, and S. Krishnamurthy Cellular responses to cisplatin-induced DNA damage J. Nucleic Acids 2010 2010
20. A. Basu, and U. Sivaprasad Protein kinase cepsilon makes the life and death decision Cell. Signal. 19 2007 1633 1642
21. A. Basu, and H. Tu Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta Biochem. Biophys. Res. Commun. 334 2005 1068 1073
22. D.J. Beck, and R.R. Brubaker Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli J. Bacteriol. 116 1973 1247 1252
23. C.A. Belfi, S. Chatterjee, D.M. Gosky, S.J. Berger, and N.A. Berger Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation Biochem. Biophys. Res. Commun. 257 1999 361 368
24. +cells display stem-like features and are spared by cisplatin treatment Proc. Natl. Acad. Sci. U.S.A. 106 2009 16281 16286
25. D.P. Brazil, and B.A. Hemmings Ten years of protein kinase B signalling: a hard Akt to follow Trends Biochem. Sci. 26 2001 657 664
26. A. Brozovic, A. Ambriovic-Ristov, and M. Osmak The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin Crit. Rev. Toxicol. 40 2010 347 359
27. A. Brozovic, S. Simaga, and M. Osmak Induction of heat shock protein 70 in drug-resistant cells by anticancer drugs and hyperthermia Neoplasma 48 2001 99 103
28. J.M. Byun, D.H. Jeong, D.S. Lee, J.R. Kim, S.G. Park, M.S. Kang, Y.N. Kim, K.B. Lee, M.S. Sung, and K.T. Kim Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer Oncol. Rep. 29 2013 1540 1546
29. R. Canetta, M. Rozencweig, and S.K. Carter Carboplatin: the clinical spectrum to date Cancer Treat. Rev. 12 Suppl. A 1985 S125 S136
30. P. Carloni, and W. Andreoni Platinum-modified nucleobase pairs in the solid state: a theoretical study J. Phys. Chem. 100 1996 17797 17800
31. P. Carloni, M. Sprik, and W. Andreoni Key steps of the cis-platin-DNA interaction: density functional theory-based molecular dynamics simulations J. Phys. Chem. B 104 2000 823 835
32. A.A. Caro, and A.I. Cederbaum Oxidative stress, toxicology, and pharmacology of CYP2E1 Annu. Rev. Pharmacol. Toxicol. 44 2004 27 42
33. R. Cetin, E. Devrim, B. Kilicoglu, A. Avci, O. Candir, and I. Durak Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods J. Appl. Toxicol. 26 2006 42 46
34. S. Chian, Y.Y. Li, X.J. Wang, and X.W. Tang Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the nrf2 pathway Asian Pac. J. Cancer Prev. 15 2014 2911 2916
35. L. Chang, and M. Karin Mammalian MAP kinase signalling cascades Nature 410 2001 37 40
36. G. Chen, M. Huynh, L. Fehrenbacher, H. West, P.N. Lara Jr., L.L. Yavorkovsky, M. Russin, D. Goldstein, D. Gandara, and D. Lau Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer J. Clin. Oncol. 27 2009 1401 1404
37. J.M. Cho, S. Manandhar, H.R. Lee, H.M. Park, and M.K. Kwak Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance Cancer Lett. 260 2008 96 108
38. N. Colombo, C. Sessa, F. Landoni, E. Sartori, S. Pecorelli, and C. Mangioni Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary Obstet. Gynecol. 67 1986 265 268
39. E.T. Creagan, J.E. Woods, A.J. Schutt, and J.R. O'Fallon Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancer Cancer 52 1983 2007 2010
40. L. Crino, G. Scagliotti, M. Marangolo, F. Figoli, M. Clerici, M.F. De, F. Salvati, G. Cruciani, L. Dogliotti, F. Pucci, A. Paccagnella, V. Adamo, G. Altavilla, P. Incoronato, M. Trippetti, A.M. Mosconi, A. Santucci, S. Sorbolini, C. Oliva, and M. Tonato Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study J. Clin. Oncol. 15 1997 297 303
41. A. Cuadrado, V. Lafarga, P.C. Cheung, I. Dolado, S. Llanos, P. Cohen, and A.R. Nebreda A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis EMBO J. 26 2007 2115 2126
42. B.S. Cummings, J.M. Lasker, and L.H. Lash Expression of glutathione-dependent enzymes and cytochrome P450s in freshly isolated and primary cultures of proximal tubular cells from human kidney J. Pharmacol. Exp. Ther. 293 2000 677 685
43. F.E. de Jongh, R.N. van Veen, S.J. Veltman, W.R. de, Burg M.E. van der, Bent M.J. van den, A.S. Planting, W.J. Graveland, G. Stoter, and J. Verweij Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients Br. J. Cancer 88 2003 1199 1206
44. M.P. Decatris, S. Sundar, and K.J. O'Byrne Platinum-based chemotherapy in metastatic breast cancer: current status Cancer Treat. Rev. 30 2004 53 81
45. R.D. DeHaan, E.M. Yazlovitskaya, and D.L. Persons Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase Cancer Chemother. Pharmacol. 48 2001 383 388
46. L. Deng, E. Zhang, and C. Chen Synergistic interaction of beta-galactosyl-pyrrolidinyl diazeniumdiolate with cisplatin against three tumor cells Arch. Pharm. Res. 36 2013 619 625
47. B. Desoize Cancer and metals and metal compounds: part I - carcinogenesis Crit. Rev. Oncol. Hematol. 42 2002 1 3
48. B. Desoize, and C. Madoulet Particular aspects of platinum compounds used at present in cancer treatment Crit. Rev. Oncol. Hematol. 42 2002 317 325
49. D.V. Deubel On the competition of the purine bases, functionalities of peptide side chains, and protecting agents for the coordination sites of dicationic cisplatin derivatives J. Am. Chem. Soc. 124 2002 5834 5842
50. D.V. Deubel Factors governing the kinetic competition of nitrogen and sulfur ligands in cisplatin binding to biological targets J. Am. Chem. Soc. 126 2004 5999 6004
51. F.H. Dexeus, C.J. Logothetis, A. Sella, R. Amato, R. Kilbourn, K. Fitz, and A. Striegel Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract J. Urol. 146 1991 1284 1287
52. S. Dhar, N. Kolishetti, S.J. Lippard, and O.C. Farokhzad Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo Proc. Natl. Acad. Sci. U.S.A. 108 2011 1850 1855
53. I.W. Dimery, S.S. Legha, M. Shirinian, and W.K. Hong Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma J. Clin. Oncol. 8 1990 1056 1062
54. N.A. dos Santos, N.M. Martins, C. Curti, M.L. Pires Bianchi, and A.C. dos Santos Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats Chem. Biol. Interact. 170 2007 177 186
55. A.I. Dreyfuss, J.R. Clark, B.G. Fallon, M.R. Posner, C.M. Norris Jr., and D. Miller Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin Cancer 60 1987 2869 2872
56. N. Du, X. Li, F. Li, H. Zhao, Z. Fan, J. Ma, Y. Fu, and H. Kang Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancermediated malignant pleural effusion Oncol. Rep. 29 2013 2332 2340
57. A.I. Einzig, H. Hochster, P.H. Wiernik, D.L. Trump, J.P. Dutcher, E. Garowski, J. Sasloff, and T.J. Smith A phase II study of taxol in patients with malignant melanoma Investig. New Drugs 9 1991 59 64
58. A.I. Einzig, P.H. Wiernik, J. Sasloff, C.D. Runowicz, and G.L. Goldberg Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma J. Clin. Oncol. 10 1992 1748 1753
59. M.A. Eisenberger Supporting evidence for an active treatment program for advanced salivary gland carcinomas Cancer Treat. Rep. 69 1985 319 321
60. A.A. Forastiere Paclitaxel (Taxol) for the treatment of head and neck cancer Semin. Oncol. 21 1994 49 52
61. H.N. Fraval, C.J. Rawlings, and J.J. Roberts Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus Mutat. Res. 51 1978 121 132
62. M. Frezza, S. Hindo, D. Chen, A. Davenport, S. Schmitt, D. Tomco, and Q.P. Dou Novel metals and metal complexes as platforms for cancer therapy Curr. Pharm. Des. 16 2010 1813 1825
63. S. Fujii, S. Kitano, K. Ikenaka, and T. Shirasaka Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents Gann 70 1979 209 214
64. R.S. Go, and A.A. Adjei Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J. Clin. Oncol. 17 1999 409 422
65. J.G. Gong, A. Costanzo, H.Q. Yang, G. Melino, W.G. Kaelin Jr., M. Levrero, and J.Y. Wang The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage Nature 399 1999 806 809
66. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
67. D.S. Goodsell The molecular perspective: cisplatin Stem Cells 24 2006 514 515
68. S.C. Gupta, D. Hevia, S. Patchva, B. Park, W. Koh, and B.B. Aggarwal Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy Antioxid. Redox Signal. 16 2012 1295 1322
69. M.B. Hampton, and S. Orrenius Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis FEBS Lett. 414 1997 552 556
70. J.T. Hartmann, L.M. Fels, S. Knop, H. Stolt, L. Kanz, and C. Bokemeyer A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors Investig. New Drugs 18 2000 281 289
71. J.T. Hartmann, and H.P. Lipp Toxicity of platinum compounds Expert Opin. Pharmacother. 4 2003 889 901
72. J. Hayakawa, S. Mittal, Y. Wang, K.S. Korkmaz, E. Adamson, C. English, M. Ohmichi, M. McClelland, and D. Mercola Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress Mol. Cell. 16 2004 521 535
73. J. Hayakawa, M. Ohmichi, H. Kurachi, H. Ikegami, A. Kimura, T. Matsuoka, H. Jikihara, D. Mercola, and Y. Murata Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line J. Biol. Chem. 274 1999 31648 31654
74. J. Hayakawa, M. Ohmichi, H. Kurachi, Y. Kanda, K. Hisamoto, Y. Nishio, K. Adachi, K. Tasaka, T. Kanzaki, and Y. Murata Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin Cancer Res. 60 2000 5988 5994
75. Hazardous Substances Data Bank.National Library of Medicine. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen ?HSDB and search on CAS number. (accessed 19.03.14.).
76. J. Hirata, Y. Kikuchi, T. Kita, E. Imaizumi, T. Tode, K. Ishii, K. Kudoh, and I. Nagata Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine Int. J. Cancer 55 1993 521 527
77. R. Hitt, D. Castellano, M. Hidalgo, R. Garcia-Carbonero, M. Pena, A. Brandariz, J.M. Millan, J.J. Alvarez Vincent, and H. Cortes-Funes Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck Ann. Oncol. 9 1998 1347 1349
78. F.A. Holmes, R.S. Walters, R.L. Theriault, A.D. Forman, L.K. Newton, M.N. Raber, A.U. Buzdar, D.K. Frye, and G.N. Hortobagyi Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer J. Natl. Cancer Inst. 83 1991 1797 1805
79. A.K. Holzer, G.H. Manorek, and S.B. Howell Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin Mol. Pharmacol. 70 2006 1390 1394
80. T.G. Huang, S.M. Ip, W.S. Yeung, and H.Y. Ngan Changes in p21WAF1, pRb, Mdm-2, Bax and Bcl-2 expression in cervical cancer cell lines transfected with a p53 expressing adenovirus Eur. J. Cancer 36 2000 249 256
81. IARC Cisplatin. In Some Antineoplastic and Immunosuppressive Agents IARCMonographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans 1981 International Agency for Research on Cancer Lyon, France 151 164
82. Y. Ichinose, N. Takanashi, T. Yano, H. Asoh, H. Yokoyama, K. Tayama, N. Hara, and M. Ohta A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable non small cell lung cancer Cancer 75 1995 2677 2680
83. Y. Ichinose, K. Yosimori, S. Yoneda, M. Kuba, S. Kudoh, and H. Niitani UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group Cancer 88 2000 318 323
84. M. Iraz, M.T. Kalcioglu, A. Kizilay, and E. Karatas Aminoguanidine prevents ototoxicity induced by cisplatin in rats Ann. Clin. Lab. Sci. 35 2005 329 335
85. S. Iseri, F. Ercan, N. Gedik, M. Yuksel, and I. Alican Simvastatin attenuates cisplatin-induced kidney and liver damage in rats Toxicology 230 2007 256 264
86. S. Ishida, J. Lee, D.J. Thiele, and I. Herskowitz Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals Proc. Natl. Acad. Sci. U.S.A. 99 2002 14298 14302
87. S. Isonishi, P.A. Andrews, and S.B. Howell Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate J. Biol. Chem. 265 1990 3623 3627
88. Y. Iwasaki, K. Nagata, M. Nakanishi, A. Natuhara, Y. Kubota, M. Ueda, T. Arimoto, and H. Hara Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer Chest 128 2005 2268 2273
89. M. Jennerwein, and P.A. Andrews Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II) Drug Metab. Dispos. 23 1995 178 184
90. G.L. Johnson, and R. Lapadat Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases Science 298 2002 1911 1912
91. S.W. Johnson, D. Shen, I. Pastan, M.M. Gottesman, and T.C. Hamilton Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines Exp. Cell Res. 226 1996 133 139
92. E.V. Jones, M.J. Dickman, and A.J. Whitmarsh Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase Biochem. J. 405 2007 617 623
93. S.S. Kakar, V.R. Jala, and M.Y. Fong Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines Biochem. Biophys. Res. Commun. 423 2012 819 825
94. A. Kart, Y. Cigremis, M. Karaman, and H. Ozen Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit Exp. Toxicol. Pathol. 62 2010 45 52
95. L. Kelland The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 7 2007 573 584
96. A.B. Khan, B.J. D'Souza, M.D. Wharam, L.A. Champion, L.F. Sinks, S.Y. Woo, D.C. McCullough, and B.G. Leventhal Cisplatin therapy in recurrent childhood brain tumors Cancer Treat. Rep. 66 1982 2013 2020
97. S. Kharbanda, P. Pandey, T. Yamauchi, S. Kumar, M. Kaneki, V. Kumar, A. Bharti, Z.M. Yuan, L. Ghanem, A. Rana, R. Weichselbaum, G. Johnson, and D. Kufe Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage Mol. Cell. Biol. 20 2000 4979 4989
98. Y.H. Kim, S.W. Shin, B.S. Kim, J.H. Kim, J.G. Kim, Y.J. Mok, C.S. Kim, H.S. Rhyu, J.H. Hyun, and J.S. Kim Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma Cancer 85 1999 295 301
99. F.C. Kischkel, S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P.H. Krammer, and M.E. Peter Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor EMBO J. 14 1995 5579 5588
100. M. Koch, M.L. Krieger, D. Stolting, N. Brenner, M. Beier, U. Jaehde, M. Wiese, H.D. Royer, and G. Bendas Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling Biochem. Pharmacol. 85 2013 1077 1090
101. W. Koizumi, H. Narahara, T. Hara, A. Takagane, T. Akiya, M. Takagi, K. Miyashita, T. Nishizaki, O. Kobayashi, W. Takiyama, Y. Toh, T. Nagaie, S. Takagi, Y. Yamamura, K. Yanaoka, H. Orita, and M. Takeuchi S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol. 9 2008 215 221
102. C. Kosmas, N.B. Tsavaris, N.A. Malamos, M. Vadiaka, and C. Koufos Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer J. Clin. Oncol. 19 2001 119 126
103. M.K. Kuhlmann, G. Burkhardt, and H. Kohler Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application Nephrol. Dial. Transplant. 12 1997 2478 2480
104. J.K.-C. Lau, and D.V. Deubel Hydrolysis of the anticancer drug cisplatin: pitfalls in the interpretation of quantum chemical calculations J. Chem. Theory Comput. 2 2005 103 106
105. C.T. Le, D. Brisgand, J.Y. Douillard, J.L. Pujol, V. Alberola, A. Monnier, A. Riviere, P. Lianes, P. Chomy, and S. Cigolari Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients J. Clin. Oncol. 12 1994 360 367
106. S.S. Legha, S. Ring, N. Papadopoulos, M. Raber, and R.S. Benjamin A phase II trial of taxol in metastatic melanoma Cancer 65 1990 2478 2481
107. D. Levy, Y. Adamovich, N. Reuven, and Y. Shaul Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage Mol. Cell. 29 2008 350 361
108. Y. Liao, X. Lu, C. Lu, G. Li, Y. Jin, and H. Tang Selection of agents for prevention of cisplatin-induced hepatotoxicity Pharmacol. Res. 57 2008 125 131
109. B.W. Light, W.D. Yu, M.C. McElwain, D.M. Russell, D.L. Trump, and C.S. Johnson Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system Cancer Res. 57 1997 3759 3764
110. C.C. Lin, H.H. Yeh, W.L. Huang, J.J. Yan, W.W. Lai, W.P. Su, H.H. Chen, and W.C. Su Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway Am. J. Respir. Cell Mol. Biol. 49 2013 241 250
111. J. Lin, Q. Zhang, Y. Lu, W. Xue, Y. Xu, Y. Zhu, and X. Hu Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1 PLoS One 9 2014 e98418
112. X. Lin, T. Okuda, A. Holzer, and S.B. Howell The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae Mol. Pharmacol. 62 2002 1154 1159
113. J.R. Liu, A.W. Opipari, L. Tan, Y. Jiang, Y. Zhang, H. Tang, and G. Nunez Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance Cancer Res. 62 2002 924 931
114. S. Llanos, and M. Serrano Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway Cell Cycle 9 2010 4005 4012
115. H.T. Lynch, M.J. Casey, C.L. Snyder, C. Bewtra, J.F. Lynch, M. Butts, and A.K. Godwin Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management Mol. Oncol. 3 2009 97 137
116. N. Machuy, K. Rajalingam, and T. Rudel Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis Cell Death. Differ. 11 2004 290 300
117. A. Mandic, J. Hansson, S. Linder, and M.C. Shoshan Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling J. Biol. Chem. 278 2003 9100 9106
118. H.H. Mansour, H.F. Hafez, and N.M. Fahmy Silymarin modulates Cisplatin-induced oxidative stress and hepatotoxicity in rats J. Biochem. Mol. Biol. 39 2006 656 661
119. Y. Mantri, and M.H. Baik Computational Studies: Cisplatin Encyclopedia of Inorganic Chemistry 2006 John Wiley & Sons, Ltd. Hoboken, New Jersey, USA
120. C.J. Marshall Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation Cell 80 1995 179 185
121. J.L. Martindale, and N.J. Holbrook Cellular response to oxidative stress: signaling for suicide and survival J. Cell. Physiol. 192 2002 1 15
122. M. Matsuki, A. Takahashi, S. Katou, A. Takayanagi, Y. Takagi, and K. Kamata Pathological complete response to gemcitabine and cisplatin chemotherapy for advanced upper tract urothelial carcinoma: a case report Nihon Hinyokika Gakkai Zasshi 104 2013 33 37
123. W.P. McGuire, E.K. Rowinsky, N.B. Rosenshein, F.C. Grumbine, D.S. Ettinger, D.K. Armstrong, and R.C. Donehower Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms Ann. Intern. Med. 111 1989 273 279
124. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look, D.L. Clarke-Pearson, and M. Davidson Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
125. F. Meng, G. Sun, M. Zhong, Y. Yu, and M.A. Brewer Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer Br. J. Cancer 108 2013 579 586
126. M. Milczarek, S. Rosinska, M. Psurski, M. Maciejewska, A. Kutner, and J. Wietrzyk Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin Anticancer Res. 33 2013 433 444
127. D. Minami, N. Takigawa, H. Takeda, M. Takata, N. Ochi, E. Ichihara, A. Hisamoto, K. Hotta, M. Tanimoto, and K. Kiura Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells Mol. Cancer Res. 11 2013 140 148
128. W.K. Murphy, F.V. Fossella, R.J. Winn, D.M. Shin, H.E. Hynes, H.M. Gross, E. Davilla, J. Leimert, H. Dhingra, and M.N. Raber Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer J. Natl. Cancer Inst. 85 1993 384 388
129. S. Nagpal, S. Na, and R. Rathnachalam Noncalcemic actions of vitamin D receptor ligands Endocr. Rev. 26 2005 662 687
130. G. Natarajan, R. Malathi, and E. Holler Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited Biochem. Pharmacol. 58 1999 1625 1629
131. M. Naziroglu, A. Karaoglu, and A.O. Aksoy Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats Toxicology 195 2004 221 230
132. A. Nehme, R. Baskaran, S. Nebel, D. Fink, S.B. Howell, J.Y. Wang, and R.D. Christen Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells Br. J. Cancer 79 1999 1104 1110
133. M.U. Nessa, P. Beale, C. Chan, J.Q. Yu, and F. Huq Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models Anticancer Res. 31 2011 3789 3797
134. A.C. Newton Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm Biochem. J. 370 2003 361 371
135. G.S. Nikolov, N. Trendafilova, H. Schönenberger, R. Gust, J. Kritzenberger, and H. Yersin Molecular mechanical and quantum chemical study on the species involved in the hydrolysis of cis-diamminedichloroplatinum(II) and substituted bis(ethylenediamine)dichloroplatinum(II) complexes Part I. Reactants and products Inorg. Chim. Acta 217 1994 159 170
136. Y. Nishizuka Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C Science 258 1992 607 614
137. G. Nowak Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells J. Biol. Chem. 277 2002 43377 43388
138. G. Nunez, M.A. Benedict, Y. Hu, and N. Inohara Caspases: the proteases of the apoptotic pathway Oncogene 17 1998 3237 3245
139. T. Ohta, M. Ohmichi, T. Hayasaka, S. Mabuchi, M. Saitoh, J. Kawagoe, K. Takahashi, H. Igarashi, B. Du, M. Doshida, I.G. Mirei, T. Motoyama, K. Tasaka, and H. Kurachi Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models Endocrinology 147 2006 1761 1769
140. T. Ozben Oxidative stress and apoptosis: impact on cancer therapy J. Pharm. Sci. 96 2007 2181 2196
141. P.N.V. Pavankumar, P. Seetharamulu, S. Yao, J.D. Saxe, D.G. Reddy, and F.H. Hausheer Comprehensive ab initio quantum mechanical and molecular orbital (MO) analysis of cisplatin: structure, bonding, charge density, and vibrational frequencies J. Comput. Chem. 20 1999 365 382
142. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J. Clin. 55 2005 74 108
143. J. Parness, and S.B. Horwitz Taxol binds to polymerized tubulin in vitro J. Cell Biol. 91 1981 479 487
144. D.L. Persons, E.M. Yazlovitskaya, W. Cui, and J.C. Pelling Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin Clin. Cancer Res. 5 1999 1007 1014
145. J.P. Pignon, H. Tribodet, G.V. Scagliotti, J.Y. Douillard, F.A. Shepherd, R.J. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, S.G. Spiro, E. Rolland, R. Fossati, D. Aubert, K. Ding, D. Waller, and C.T. Le Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J. Clin. Oncol. 26 2008 3552 3559
146. R. Pinto-Leite, R. Arantes-Rodrigues, C. Palmeira, B. Colaco, C. Lopes, A. Colaco, C. Costa, V.M. da Silva, P. Oliveira, and L. Santos Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer Biomed. Pharmacother. 67 2013 116 121
147. M. Previati, I. Lanzoni, E. Corbacella, S. Magosso, V. Guaran, A. Martini, and S. Capitani Cisplatin-induced apoptosis in human promyelocytic leukemia cells Int. J. Mol. Med. 18 2006 511 516
148. E. Rodriguez-Fernandez, J.L. Manzano, A. Alonso, M.J. Almendral, M. Perez-Andres, A. Orfao, and J.J. Criado Fluorescent cisplatin analogues and cytotoxic activity Curr. Med. Chem. 16 2009 4314 4327
149. b. Rosenberg, L. Vancamp, and T. Krigas Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode Nature 205 1965 698 699
150. S.Y. Saad, T.A. Najjar, and M. Alashari Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats Clin. Exp. Pharmacol. Physiol. 31 2004 862 867
151. G.S. Salvesen, and J.M. Abrams Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies Oncogene 23 2004 2774 2784
152. G.S. Salvesen, and V.M. Dixit Caspases: intracellular signaling by proteolysis Cell 91 1997 443 446
153. A. Saramaki, C.M. Banwell, M.J. Campbell, and C. Carlberg Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor Nucleic Acids Res. 34 2006 543 554
154. G. Sarosy, E. Kohn, D.A. Stone, M. Rothenberg, J. Jacob, D.O. Adamo, F.P. Ognibene, R.E. Cunnion, and E. Reed Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer J. Clin. Oncol. 10 1992 1165 1170
155. H.I. Scher A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J. Urol. 148 1992 1625 1626
156. E. Shaili Platinum anticancer drugs and photochemotherapeutic agents: recent advances and future developments Sci. Prog. 97 2014 20 40
157. D.W. Shen, X.J. Liang, M.A. Gawinowicz, and M.M. Gottesman Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines Mol. Pharmacol. 66 2004 789 793
158. D.W. Shen, X.J. Liang, T. Suzuki, and M.M. Gottesman Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance Mol. Pharmacol. 69 2006 1383 1388
159. D.W. Shen, L.M. Pouliot, M.D. Hall, and M.M. Gottesman Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes Pharmacol. Rev. 64 2012 706 721
160. X. Shi, S. Wu, Y. Yang, L. Tang, Y. Wang, J. Dong, B. Lu, G. Jiang, and W. Zhao AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells Tumour Biol. 35 2014 7035 7045
161. A. Shrivastava, P.M. Kuzontkoski, J.E. Groopman, and A. Prasad Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy Mol. Cancer Ther. 10 2011 1161 1172
162. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
163. A. Siwinska, A. Opolski, A. Chrobak, J. Wietrzyk, E. Wojdat, A. Kutner, W. Szelejewski, and C. Radzikowski Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D Anticancer Res. 21 2001 1925 1929
164. S. Skvortsov, J. Dudas, P. Eichberger, M. Witsch-Baumgartner, J. Loeffler-Ragg, C. Pritz, V.H. Schartinger, H. Maier, J. Hall, P. Debbage, H. Riechelmann, P. Lukas, and I. Skvortsova Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC) Br. J. Cancer 110 11 2014 2677 2687
165. L. Smith, K.J. Welham, M.B. Watson, P.J. Drew, M.J. Lind, and L. Cawkwell The proteomic analysis of cisplatin resistance in breast cancer cells Oncol. Res. 16 2007 497 506
166. Y.D. Song, K.F. Zhang, D. Liu, Y.Q. Guo, D.Y. Wang, M.Y. Cui, G. Li, Y.X. Sun, J.H. Shen, X.G. Li, L. Zhang, and F.J. Shi Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin Tumour Biol. 35 7 2014 7017 7024
167. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, and R.O. Mirimanoff Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
168. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, and R.O. Mirimanoff Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996
169. M.K. Tang, H.Y. Zhou, J.W. Yam, and A.S. Wong c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2 Neoplasia 12 2010 128 138
170. The chemical book database http://www.chemicalbook.com/ProductIndex-EN.aspxand searchon product details. (accessed 21.03.14.).
171. A.M. Tsimberidou, F. Braiteh, D.J. Stewart, and R. Kurzrock Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial J. Clin. Oncol. 27 2009 6243 6250
172. J. Valle, H. Wasan, D.H. Palmer, D. Cunningham, A. Anthoney, A. Maraveyas, S. Madhusudan, T. Iveson, S. Hughes, S.P. Pereira, M. Roughton, and J. Bridgewater Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N. Engl. J. Med. 362 2010 1273 1281
173. L.M. Vargas-Roig, F.E. Gago, O. Tello, J.C. Aznar, and D.R. Ciocca Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy Int. J. Cancer 79 1998 468 475
174. M.H. von der, L. Sengelov, J.T. Roberts, S. Ricci, L. Dogliotti, T. Oliver, M.J. Moore, A. Zimmermann, and M. Arning Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J. Clin. Oncol. 23 2005 4602 4608
175. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 2005 307 320
176. H. Wang, G. Zhang, H. Zhang, F. Zhang, B. Zhou, F. Ning, H.S. Wang, S.H. Cai, and J. Du Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/beta-catenin/Snail signaling pathway Eur. J. Pharmacol. 723 2014 156 166
177. J. Wang, and G.S. Wu Role of autophagy in cisplatin resistance in ovarian cancer cells J. Biol. Chem. 24 13 2014 17163 17173
178. X. Wang, J.L. Martindale, and N.J. Holbrook Requirement for ERK activation in cisplatin-induced apoptosis J. Biol. Chem. 275 2000 39435 39443
179. R.B. Weiss, and M.C. Christian New cisplatin analogues in development. A review Drugs 46 1993 360 377
180. S.E. Winograd-Katz, and A. Levitzki Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor Oncogene 25 2006 7381 7390
181. X.M. Xu, Y. Zhang, D. Qu, H.B. Liu, X. Gu, G.Y. Jiao, and L. Zhao Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro Exp. Ther. Med. 5 2013 707 710
182. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334 2007 115 124
183. P.Y. Yeh, S.E. Chuang, K.H. Yeh, Y.C. Song, C.K. Ea, and A.L. Cheng Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation Biochem.Pharmacol. 63 2002 1423 1430
184. H.R. Yilmaz, M. Iraz, S. Sogut, H. Ozyurt, Z. Yildirim, O. Akyol, and S. Gergerlioglu The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats Pharmacol. Res. 50 2004 287 290
185. H.R. Yilmaz, S. Sogut, B. Ozyurt, F. Ozugurlu, S. Sahin, B. Isik, E. Uz, and H. Ozyurt The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester Toxicol. Ind. Health 21 2005 67 73
186. D.R. Youlden, S.M. Cramb, and P.D. Baade The international epidemiology of lung cancer: geographical distribution and secular trends J. Thorac. Oncol. 3 2008 819 831
187. M.I. Yousef, A.A. Saad, and L.K. El-Shennawy Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats Food Chem. Toxicol. 47 2009 1176 1183
188. Y. Zhang, Z. Guo, and X.Z. You Hydrolysis theory for cisplatin and its analogues based on density functional studies J. Am. Chem. Soc. 123 2001 9378 9387